Literature DB >> 32038909

Looking for the high way in EGFR-positive non-small cell lung cancer through the evaluation of survival endpoints.

Antonio Passaro1, Filippo de Marinis1.   

Abstract

Entities:  

Year:  2019        PMID： 32038909      PMCID： PMC6987339          DOI： 10.21037/tlcr.2019.06.04

Source DB:  PubMed          Journal:  Transl Lung Cancer Res        ISSN： 2218-6751


× No keyword cloud information.
  30 in total

1.  Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial.

Authors:  Yi-Long Wu; Ying Cheng; Xiangdong Zhou; Ki Hyeong Lee; Kazuhiko Nakagawa; Seiji Niho; Fumito Tsuji; Rolf Linke; Rafael Rosell; Jesus Corral; Maria Rita Migliorino; Adam Pluzanski; Eric I Sbar; Tao Wang; Jane Liang White; Sashi Nadanaciva; Rickard Sandin; Tony S Mok
Journal:  Lancet Oncol       Date:  2017-09-25       Impact factor: 41.316

2.  Improved overall survival following tyrosine kinase inhibitor (TKI) treatment in NSCLC-are we making progress?

Authors:  Klaus Fenchel; Stephen P Dale; Wolfram C M Dempke
Journal:  Transl Lung Cancer Res       Date:  2016-08

3.  Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial.

Authors:  Tetsuya Mitsudomi; Satoshi Morita; Yasushi Yatabe; Shunichi Negoro; Isamu Okamoto; Junji Tsurutani; Takashi Seto; Miyako Satouchi; Hirohito Tada; Tomonori Hirashima; Kazuhiro Asami; Nobuyuki Katakami; Minoru Takada; Hiroshige Yoshioka; Kazuhiko Shibata; Shinzoh Kudoh; Eiji Shimizu; Hiroshi Saito; Shinichi Toyooka; Kazuhiko Nakagawa; Masahiro Fukuoka
Journal:  Lancet Oncol       Date:  2009-12-18       Impact factor: 41.316

4.  CNS Response to Osimertinib Versus Standard Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients With Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer.

Authors:  Thanyanan Reungwetwattana; Kazuhiko Nakagawa; Byoung Chul Cho; Manuel Cobo; Eun Kyung Cho; Alessandro Bertolini; Sabine Bohnet; Caicun Zhou; Ki Hyeong Lee; Naoyuki Nogami; Isamu Okamoto; Natasha Leighl; Rachel Hodge; Astrid McKeown; Andrew P Brown; Yuri Rukazenkov; Suresh S Ramalingam; Johan Vansteenkiste
Journal:  J Clin Oncol       Date:  2018-08-28       Impact factor: 44.544

5.  Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.

Authors:  Thomas J Lynch; Daphne W Bell; Raffaella Sordella; Sarada Gurubhagavatula; Ross A Okimoto; Brian W Brannigan; Patricia L Harris; Sara M Haserlat; Jeffrey G Supko; Frank G Haluska; David N Louis; David C Christiani; Jeff Settleman; Daniel A Haber
Journal:  N Engl J Med       Date:  2004-04-29       Impact factor: 91.245

6.  Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma.

Authors:  Tony S Mok; Yi-Long Wu; Sumitra Thongprasert; Chih-Hsin Yang; Da-Tong Chu; Nagahiro Saijo; Patrapim Sunpaweravong; Baohui Han; Benjamin Margono; Yukito Ichinose; Yutaka Nishiwaki; Yuichiro Ohe; Jin-Ji Yang; Busyamas Chewaskulyong; Haiyi Jiang; Emma L Duffield; Claire L Watkins; Alison A Armour; Masahiro Fukuoka
Journal:  N Engl J Med       Date:  2009-08-19       Impact factor: 91.245

7.  Improvement in Overall Survival in a Randomized Study That Compared Dacomitinib With Gefitinib in Patients With Advanced Non-Small-Cell Lung Cancer and EGFR-Activating Mutations.

Authors:  Tony S Mok; Ying Cheng; Xiangdong Zhou; Ki Hyeong Lee; Kazuhiko Nakagawa; Seiji Niho; Min Lee; Rolf Linke; Rafael Rosell; Jesus Corral; Maria Rita Migliorino; Adam Pluzanski; Eric I Sbar; Tao Wang; Jane Liang White; Yi-Long Wu
Journal:  J Clin Oncol       Date:  2018-06-04       Impact factor: 44.544

8.  Postprogression Outcomes for Osimertinib versus Standard-of-Care EGFR-TKI in Patients with Previously Untreated EGFR-mutated Advanced Non-Small Cell Lung Cancer.

Authors:  David Planchard; Michael J Boyer; Jong-Seok Lee; Arunee Dechaphunkul; Parneet K Cheema; Toshiaki Takahashi; Jhanelle E Gray; Marcello Tiseo; Suresh S Ramalingam; Alexander Todd; Astrid McKeown; Yuri Rukazenkov; Yuichiro Ohe
Journal:  Clin Cancer Res       Date:  2019-01-18       Impact factor: 12.531

9.  Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer.

Authors:  Jean-Charles Soria; Yuichiro Ohe; Johan Vansteenkiste; Thanyanan Reungwetwattana; Busyamas Chewaskulyong; Ki Hyeong Lee; Arunee Dechaphunkul; Fumio Imamura; Naoyuki Nogami; Takayasu Kurata; Isamu Okamoto; Caicun Zhou; Byoung Chul Cho; Ying Cheng; Eun Kyung Cho; Pei Jye Voon; David Planchard; Wu-Chou Su; Jhanelle E Gray; Siow-Ming Lee; Rachel Hodge; Marcelo Marotti; Yuri Rukazenkov; Suresh S Ramalingam
Journal:  N Engl J Med       Date:  2017-11-18       Impact factor: 91.245

Review 10.  Optimizing outcomes in EGFR mutation-positive NSCLC: which tyrosine kinase inhibitor and when?

Authors:  Nicolas Girard
Journal:  Future Oncol       Date:  2018-01-16       Impact factor: 3.404
View more
  1 in total

1.  Establishment of multiplex allele-specific blocker PCR for enrichment and detection of 4 common EGFR mutations in non-small cell lung cancer.

Authors:  Hongyuan Chen; Jie Zhang; Hong-Yan Chen; Bo Su; Daru Lu
Journal:  Ann Transl Med       Date:  2020-11
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.